Shares of HIGHTIDE-B (02511) have climbed more than 5% in Monday's Hong Kong trading session, advancing 5.44% to HK$3.295 at the time of writing, with turnover reaching HK$12.61 million.

On the news front, Guozheng International highlighted in a recent research note that China's National Medical Products Administration accepted the new drug application for HTD1801 targeting type 2 diabetes mellitus (T2DM) back in March 2026. Following that milestone, the phase III clinical data for HTD1801 combined with metformin was published in the NEJM Evidence journal in June 2026.

Meanwhile, HIGHTIDE-B has also presented clinical research outcomes for HTD1801 at numerous international medical conferences, demonstrating the drug's efficacy and safety profile in treating T2DM. While awaiting regulatory approval, the company is actively exploring commercialization pathways, seeking partners that possess robust sales networks within China and specialized expertise in the T2DM therapeutic area.

Furthermore, the brokerage noted that in July 2026, China released an expert consensus on the evaluation, diagnosis, and management of cardiovascular-kidney-metabolic syndrome, which for the first time established a Chinese-defined framework spanning the metabolism-cardiovascular-kidney-liver axis with staging criteria from 0 to 4, while incorporating metabolic dysfunction-associated steatotic liver disease into key complication pathways.

Given that HTD1801 delivers multi-target benefits covering glucose reduction, lipid lowering, kidney protection, and liver preservation, Guozheng International believes the drug aligns remarkably well with this new consensus and holds substantial growth potential going forward.